Wave Life Sciences Shareholders Approve Key Proposals Amid Financial Challenges

Wave Life Sciences shareholders have approved key proposals, including an amendment to the 2021 Equity Incentive Plan and the re-election of nine directors. The meeting also saw the re-appointment of KPMG LLP as the company's auditor and the approval of compensation plans for non-employee directors and executive officers. The company's strong cash position and favorable analyst sentiment are positive, but financial instability remains a concern. The overall stock score is Neutral.